Your session is about to expire
← Back to Search
Study Summary
This trial is studying a drug called frexalimab to see if it can help delay disability progression in people with a certain type of multiple sclerosis. The study will last between 27 to
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any available slots for patients to participate in this research study?
"Indeed, the data available on clinicaltrials.gov confirms that this research trial is currently in the recruitment phase. The initial posting date for this study was December 27th, 2023 and the most recent update occurred on January 26th, 2024. The study aims to enroll a total of 858 participants spread across ten different research sites."
Which specific criteria must individuals meet in order to be considered eligible for participation in this clinical study?
"This clinical trial aims to recruit a total of 858 individuals, between the ages of 18 and 60, who have been diagnosed with multiple sclerosis (MS). To be eligible for participation, patients must meet the following criteria: "
What is the current number of participants enrolled in this clinical investigation?
"A total of 858 eligible participants are required to partake in this research endeavor. Potential subjects have the opportunity to enroll at various locations, such as Sharlin Health & Neurology Site Number: 8400016 situated in Ozark, Missouri and Regina Berkovich, MD, PhD Site Number: 8400005 located in West Hollywood, California."
Is there an age restriction for participants in this medical trial, specifically excluding those under the age of 30?
"Patients between the ages of 18 and 60 are eligible to participate in this clinical trial. However, there are separate trials available for patients under the age of 18 (35 trials) and patients over the age of 65 (385 trials)."
Are there a considerable number of medical facilities across the United States conducting this research study?
"There are 10 active study sites participating in this trial, including Sharlin Health & Neurology Site Number: 8400016 located in Ozark, Regina Berkovich, MD, PhD Site Number: 8400005 situated in West Hollywood, and Axiom Clinical Research of Florida Site Number: 8400049 found in Tampa. There are also additional locations available for patient enrollment at 10 other sites."
Has Frexalimab received the official endorsement of the FDA?
"Based on the study's classification as a Phase 3 trial, which indicates both efficacy and safety data have been collected from multiple rounds of testing, our team at Power rates Frexalimab with a safety score of 3."
Share this study with friends
Copy Link
Messenger